Brief: Biosynex H1 Revenue Up At EUR 225 MLN

Biosynex SA

21/07/2021 17:00

July 21 (Reuters) - BIOSYNEX SA  ALBIO.PA :

    * H1 REVENUE EUR 225.0 MILLION VERSUS EUR 44.1 MILLION YEAR
AGO
    * CONFIRMS ITS OBJECTIVE OF STRONG INCREASE IN PROFITABILITY
INDICATORS FOR FY
    * IN SHORT TERM, DECREASE IN DEMAND FOR SARS-COV-2 TESTS
WILL BE
TEMPERED BY PROGRESSION OF DELTA VARIANT AND GROWING DEMAND FROM
EMERGING COUNTRIES
    * REITERATES ITS CONFIDENCE IN ABILITY TO ACHIEVE
SUSTAINABLE AND
PROFITABLE GROWTH IN COMING YEARS
    * EXPECTS DEMAND FOR SARS-COV-2 TESTS TO DECLINE IN COMING
QUARTERS AS RESULT OF INCREASED VACCINE COVERAGE IN DEVELOPED
COUNTRIES

Source text for Eikon:  ID:nBw8HRKBca 
Further company coverage:  ALBIO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))